Drugs / doxifluridine
last change Mar 2010 re-read 9 days ago

doxifluridine

Small molecule targets TYMS via inhibition

Developed for
gastric adenocarcinoma · gastric cancer

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy3 trials
Phase 3 NCT00296335 Comparator Feb 2002 → Nov 2007 gastric adenocarcinoma Asan Medical Center Completed No outcome recorded
Phase 3 NCT00296322 Comparator Oct 2001 → Dec 2007 gastric cancer Asan Medical Center Completed No outcome recorded
Phase 4 NCT01401075 Background Mar 2006 → Apr 2008 gastric cancer Abnoba GmbH Completed No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Doxifluridine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00296335 ↗
2

NCT01401075 ↗

NCT00296322 ↗

Known as 5'-deoxy-5-fluorouridine (5'-dfur) ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Known as Capecitabine related compound b ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Known as Doxifluridina ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Known as Flutron ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Known as Fulturon ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Known as Furtulon ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Known as NSC-758890 ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Known as RO 219738 ChEMBL registry synonym — accepted as the source's own label CHEMBL1130 ↗
Action Inhibit “Thymidylate synthase inhibitor” CHEMBL1130 ↗
Modality Small molecule — CHEMBL1130 ↗
Route Oral “Doxifluridine 460-600mg/m2/day per oral for 3 months” NCT00296322 ↗
Target TYMS “Thymidylate synthase inhibitor” CHEMBL1130 ↗